Biodyne Co

Biodyne Co OCF Margin

The Operating Cash Flow Margin of Biodyne Co (314930.KQ) as of Nov 3, 2026 is 11.81 %. In the previous year, Operating Cash Flow Margin was 16.64 % — a change of -29.02% (lower).

OCF Margin

11.81 %

YoY

-29.02%

Last updated:

Operating Cash Flow Margin of Biodyne Co is 2025 11.81 % . Operating Cash Flow Margin of Biodyne Co was 2024 16.64 % . It decreases by -29.02% lower compared to the previous year.

The Biodyne Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
14.06 KRW
Jan 1, 2019
102.78 KRW
Jan 1, 2020
3.15 KRW
Jan 1, 2021
-13.41 KRW
Jan 1, 2022
21.18 KRW
Jan 1, 2023
9.91 KRW
Jan 1, 2024
16.64 KRW
Jan 1, 2025
11.81 KRW
The Biodyne Co OCF Margin history
YEAROCF MarginYoY
11.81 %-29.02%
16.64 %+68.03%
9.91 %-53.22%
21.18 %-257.89%
-13.41 %-525.46%
3.15 %-96.93%
102.78 %+631.16%
14.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biodyne Co Stock analysis

What does Biodyne Co do? Biodyne Co., Ltd. develops and sells cancer diagnosis solutions, including LBC diagnostic equipment and diagnostic reagent kits. The company's equipment lineup features PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63, and PATHPLORER ECO, targeting healthcare providers in domestic and international markets. Products are sold in Japan, Russia, Portugal, and Thailand, with domestic sales complementing overseas distribution. Revenue is generated through direct sales of diagnostic equipment and reagent kits to medical facilities and laboratories. Biodyne's primary customers are healthcare institutions requiring cancer screening and diagnostic tools, including hospitals and clinical laboratories. The firm's domestic market presence supports its international expansion into regions like Japan and Russia, where demand for advanced diagnostic solutions is growing. Sales of PATHPLORER series equipment and reagent kits form the core revenue streams, with no additional services or licensing models mentioned. The company focuses on a niche segment of cancer diagnostics, leveraging its equipment and reagent kits to serve both local and global healthcare systems. By offering standardized diagnostic solutions, Biodyne caters to the needs of medical professionals seeking reliable and efficient cancer detection methods. International markets such as Portugal and Thailand represent key growth areas alongside established domestic operations. Biodyne Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biodyne Co stock

Operating Cash Flow Margin of Biodyne Co is 11.81 % in 2025.

Operating Cash Flow Margin of Biodyne Co changed from 16.64 % to 11.81 %, representing a -29.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Biodyne Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Biodyne Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biodyne Co

All Key Metrics — Biodyne Co